Advertisement
SLNO vs VRCA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLNO is a Hold and VRCA is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SLNO’s FA Score shows that 0 FA rating(s) are green whileVRCA’s FA Score has 0 green FA rating(s).
- SLNO’s FA Score: 0 green, 5 red.
- VRCA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SLNO’s TA Score shows that 3 TA indicator(s) are bullish while VRCA’s TA Score has 5 bullish TA indicator(s).
- SLNO’s TA Score: 3 bullish, 3 bearish.
- VRCA’s TA Score: 5 bullish, 5 bearish.
Price Growth
SLNO (@Biotechnology) experienced а -0.22% price change this week, while VRCA (@Biotechnology) price change was +19.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.18%. For the same industry, the average monthly price growth was +6.79%, and the average quarterly price growth was -1.65%.
Reported Earning Dates
SLNO is expected to report earnings on Aug 06, 2025.
VRCA is expected to report earnings on Aug 12, 2025.
Industries' Descriptions
@Biotechnology (+4.18% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| SLNO | VRCA | SLNO / VRCA | |
| Capitalization | 3.69B | 59.5M | 6,208% |
| EBITDA | -173.63M | -65.9M | 263% |
| Gain YTD | 63.070 | -8.943 | -705% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 7.57M | - |
| Total Cash | 291M | 46.3M | 629% |
| Total Debt | 52.8M | 45.9M | 115% |
SLNO | VRCA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 62 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 37 | 62 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRCA's Valuation (95) in the Pharmaceuticals Major industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that VRCA’s stock grew similarly to SLNO’s over the last 12 months.
SLNO's Profit vs Risk Rating (62) in the Medical Specialties industry is somewhat better than the same rating for VRCA (100) in the Pharmaceuticals Major industry. This means that SLNO’s stock grew somewhat faster than VRCA’s over the last 12 months.
SLNO's SMR Rating (100) in the Medical Specialties industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that SLNO’s stock grew similarly to VRCA’s over the last 12 months.
SLNO's Price Growth Rating (37) in the Medical Specialties industry is in the same range as VRCA (62) in the Pharmaceuticals Major industry. This means that SLNO’s stock grew similarly to VRCA’s over the last 12 months.
SLNO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that SLNO’s stock grew similarly to VRCA’s over the last 12 months.
| SLNO | VRCA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| MACD ODDS (%) | N/A | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 85% |
| Advances ODDS (%) | 14 days ago 86% | 7 days ago 86% |
| Declines ODDS (%) | 1 day ago 86% | 1 day ago 89% |
| BollingerBands ODDS (%) | N/A | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GMYPX | 16.94 | N/A | N/A |
| Goldman Sachs Large Cap Value P | |||
| JEVNX | 9.37 | N/A | N/A |
| JHancock Disciplined Value Em Mkts EqNAV | |||
| JNUSX | 17.20 | N/A | N/A |
| JPMorgan Developed International Value L | |||
| AAAVX | 12.33 | N/A | N/A |
| DWS RREEF Real Assets R6 | |||
| GFACX | 64.58 | -1.08 | -1.64% |
| American Funds Growth Fund of Amer C | |||
SLNO and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with BRNS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then BRNS could also see price increases.
| Ticker / NAME | Correlation To SLNO | 1D Price Change % | ||
|---|---|---|---|---|
| SLNO | 100% | -2.33% | ||
| BRNS - SLNO | 56% Loosely correlated | -6.84% | ||
| KANT - SLNO | 45% Loosely correlated | -2.76% | ||
| NKTX - SLNO | 42% Loosely correlated | -5.56% | ||
| SYRE - SLNO | 41% Loosely correlated | -4.03% | ||
| SVRA - SLNO | 40% Loosely correlated | -7.18% | ||
More | ||||
VRCA and
Correlation & Price change
A.I.dvisor tells us that VRCA and PBYI have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VRCA and PBYI's prices will move in lockstep.
| Ticker / NAME | Correlation To VRCA | 1D Price Change % | ||
|---|---|---|---|---|
| VRCA | 100% | -0.89% | ||
| PBYI - VRCA | 32% Poorly correlated | -7.71% | ||
| ACOG - VRCA | 30% Poorly correlated | -6.86% | ||
| SLNO - VRCA | 29% Poorly correlated | -2.33% | ||
| FGEN - VRCA | 29% Poorly correlated | -3.54% | ||
| QURE - VRCA | 27% Poorly correlated | +1.24% | ||
More | ||||